| P50 | author | S. Vincent Rajkumar | Q61123608 |
| P2093 | author name string | D Weber | |
| | K C Anderson | |
| | R A Kyle | |
| | P Richardson | |
| | A K Stewart | |
| | ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma | |
| P2860 | cites work | Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients | Q61914822 |
| | Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden | Q70578101 |
| | A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 |
| | Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group | Q72037775 |
| | Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients | Q73883434 |
| | Treatment of multiple myeloma | Q73932761 |
| | Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group | Q77669915 |
| | A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. | Q79594487 |
| | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 |
| | Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation | Q82976014 |
| | Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance | Q24669898 |
| | Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients | Q30655745 |
| | A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 |
| | Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 |
| | High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 |
| | Multiple myeloma. | Q34362643 |
| | Prevalence of monoclonal gammopathy of undetermined significance | Q34506801 |
| | Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 |
| | Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. | Q35847679 |
| | Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma | Q35848146 |
| | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma | Q35848744 |
| | Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States | Q35849982 |
| | A prognostic index for multiple myeloma | Q36134864 |
| | A strategic framework for novel drug development in multiple myeloma | Q36860877 |
| | Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials | Q43606238 |
| | Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients | Q43966198 |
| | Clinical course of patients with relapsed multiple myeloma | Q44544763 |
| | Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 |
| | Approval summary for bortezomib for injection in the treatment of multiple myeloma | Q44951957 |
| | Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma | Q46543501 |
| | Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 |
| | Development of effective new treatments for multiple myeloma | Q46689598 |
| | Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies | Q46831332 |
| | Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma | Q46859419 |
| | Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group | Q46859424 |
| | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 |
| | Effective treatment of advanced multiple myeloma refractory to alkylating agents. | Q54474339 |
| | A long-term study of prognosis in monoclonal gammopathy of undetermined significance. | Q55035699 |
| | Erratum: International uniform response criteria for multiple myeloma | Q57904848 |
| | Impact of complete remission with intensive therapy in patients with responsive multiple myeloma | Q57905040 |
| | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | Q57905146 |
| | Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma | Q58050813 |
| | Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study | Q60203808 |
| P433 | issue | 2 | |
| P304 | page(s) | 231-239 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Clinically relevant end points and new drug approvals for myeloma | |
| P478 | volume | 22 | |